{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T03:10:05Z","timestamp":1744427405770,"version":"3.40.4"},"posted":{"date-parts":[[2025,4,12]]},"group-title":"In Review","reference-count":17,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,4,9]]},"abstract":"<title>Abstract<\/title>\n        <p><underline>Introduction:<\/underline> Mycobacterium Growth Indicator Tube (MGIT) 960 culture is critical for tuberculosis (TB) drug susceptibility testing (DST) but vulnerable to contamination. We evaluated the accuracy of Xpert MTB\/XDR, a molecular DST for isoniazid, fluoroquinolone, amikacin, and ethionamide, on to-be-discarded contaminated growth.\n<underline>Methods:<\/underline> Xpert MTB\/XDR was applied to acid-fast bacilli-negative contaminated cultures from sputum from people with rifampicin-resistant TB when Xpert MTB\/XDR on sputum was unsuccessful (not resistant or susceptible for all drugs) 1) at diagnosis (Cohort A) or 2) during treatment monitoring (Cohort B). Future DSTs within three months served as a reference standard. We determined potential care cascade improvements.\n<underline>Results:<\/underline>In Cohort A, 10% (66\/650) of people were culture-contaminated. 89% (59\/66) were contaminated growth Xpert MTB\/XDR TB-positive. Sensitivity and specificity for isoniazid, fluoroquinolone, amikacin, and ethionamide resistance were 100% [95% confidence interval (CI) 85, 100] and 100% (79, 100), 100% (59, 100) and 100% (89, 100), 100% (16, 100) and 100% (91, 100), and 100% (72, 100) and 96% (78, 100), respectively. In Cohort B, 22% (28\/129) of people with a contaminated culture were Xpert MTB\/XDR TB-positive. Of these, 57% (16\/28), 7% (2\/28), and 43% (12\/28) were isoniazid-, fluoroquinolone-, and ethionamide-resistant (in 2, 1, and 4 people respectively, this would be the first resistant result). In both cohorts, time-to-DST could improve a median (IQR) of 22 (12-42) days.\n<underline>Conclusion:<\/underline> Xpert MTB\/XDR on contaminated MGIT960 cultures had high sensitivity and specificity for DST. This approach could mitigate culture contamination\u2019s negative effects and improve gaps in the drug-resistant TB diagnostic cascade.<\/p>","DOI":"10.21203\/rs.3.rs-6409041\/v1","type":"posted-content","created":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T02:33:31Z","timestamp":1744425211000},"source":"Crossref","is-referenced-by-count":0,"title":["Waste to Worth: A diagnostic accuracy of Xpert MTB\/XDR on contaminated liquid cultures to salvage the detection of drug-resistant tuberculosis"],"prefix":"10.21203","author":[{"given":"Yonas","family":"Ghebrekristos","sequence":"first","affiliation":[{"name":"DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics,Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erick","family":"Auma","sequence":"additional","affiliation":[{"name":"DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics,Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zama","family":"Mahlobo","sequence":"additional","affiliation":[{"name":"DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics,Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rouxjeane","family":"Venter","sequence":"additional","affiliation":[{"name":"DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics,Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Beylis","sequence":"additional","affiliation":[{"name":"Division of Medical Microbiology, Department of Pathology, University of Cape Town, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay","family":"Achar","sequence":"additional","affiliation":[{"name":"DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics,Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitta","family":"Derendinger","sequence":"additional","affiliation":[{"name":"DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics,Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarishna","family":"Singh","sequence":"additional","affiliation":[{"name":"National Health Laboratory Service, Greenpoint Tuberculosis Laboratory, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Burger","sequence":"additional","affiliation":[{"name":"DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics,Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoffel","family":"Opperman","sequence":"additional","affiliation":[{"name":"National Health Laboratory Service, Greenpoint Tuberculosis Laboratory, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Warren","sequence":"additional","affiliation":[{"name":"DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics,Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grant","family":"Theron","sequence":"additional","affiliation":[{"name":"DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics,Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"1. World Health Organization. Global Tuberculosis Report 2024. Geneva: World Health Organization, 2024."},{"key":"ref2","unstructured":"2. World Health Organization. WHO Consolidated Guidelines on Tuberculosis. Module 4: Treatment - Drug-Resistant Tuberculosis Treatment, 2022 Update, 2022."},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"3. Derendinger B, Dippenaar A, de Vos M, et al. Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort study. The Lancet Microbe 2023; 4(12): e972-e82.","DOI":"10.1016\/S2666-5247(23)00172-6"},{"key":"ref4","unstructured":"4. Organization WH. Use of Xpert MTB\/RIF and Xpert MTB\/RIF Ultra on GeneXpert 10-colour instruments. Geneva, 2021."},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"5. Pillay S, Davies GR, Chaplin Ma. Xpert MTB\/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin. Cochrane Database of Systematic Reviews 2021; 2021(6).","DOI":"10.1002\/14651858.CD014841"},{"key":"ref6","unstructured":"6. Cepheid. Xpert\u00ae MTB\/XDR Brochure CE IVD 3353 English. 2024."},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"7. Ghebrekristos YT, Beylis N, Centner CM, et al. Xpert MTB\/RIF Ultra on contaminated liquid cultures for tuberculosis and rifampicin-resistance detection: a diagnostic accuracy evaluation. Lancet Microbe 2023; 4(10): e822-e9.","DOI":"10.1016\/S2666-5247(23)00169-6"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"8. Omar SV, Louw G, Ismail F, et al. Performance evaluation of the Xpert MTB\/XDR test for the detection of drug resistance to Mycobacterium tuberculosis among people diagnosed with tuberculosis in South Africa. J Clin Microbiol 2024; 62(8): e0022924.","DOI":"10.1128\/jcm.00229-24"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"9. Friedrich SO, Rachow A, Saathoff E, et al. Assessment of the sensitivity and specificity of Xpert MTB\/RIF assay as an early sputum biomarker of response to tuberculosis treatment. Lancet Respir Med 2013; 1(6): 462\u2009\u2212\u200970.","DOI":"10.1016\/S2213-2600(13)70119-X"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"10. Engelthaler DM, Streicher EM, Kelley EJ, et al. Minority Mycobacterium tuberculosis Genotypic Populations as an Indicator of Subsequent Phenotypic Resistance. Am J Respir Cell Mol Biol 2019; 61(6): 789\u2009\u2212\u200991.","DOI":"10.1165\/rcmb.2019-0178LE"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"11. Metcalfe JZ, Streicher E, Theron G, et al. Mycobacterium tuberculosis Subculture Results in Loss of Potentially Clinically Relevant Heteroresistance. Antimicrob Agents Chemother 2017; 61(11).","DOI":"10.1128\/AAC.00888-17"},{"key":"ref12","unstructured":"12. World Health Organization. Implementing the end TB strategy: the essentials, 2022 update. In: WHO, editor. Geneva; 2022."},{"key":"ref13","unstructured":"13. Siddiqi SH, R\u00fcsch-Gerdes S. MGIT procedure manual. Geneva, Switzerland: Foundation for innovative new diagnostics 2006: 41\u201351."},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"14. Pillay S, de Vos M, Derendinger B, et al. Non-actionable Results, Accuracy, and Effect of First- and Second-line Line Probe Assays for Diagnosing Drug-Resistant Tuberculosis, Including on Smear-Negative Specimens, in a High-Volume Laboratory. Clin Infect Dis 2023; 76(3): e920-e9.","DOI":"10.1093\/cid\/ciac556"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"15. Bisimwa BC, Nachega JB, Warren RM, et al. Xpert Mycobacterium tuberculosis\/Rifampicin-Detected Rifampicin Resistance is a Suboptimal Surrogate for Multidrug-resistant Tuberculosis in Eastern Democratic Republic of the Congo: Diagnostic and Clinical Implications. Clin Infect Dis 2021; 73(2): e362-e70.","DOI":"10.1093\/cid\/ciaa873"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"16. Diriba G, Kebede A, Yaregal Z, et al. Performance of Mycobacterium Growth Indicator Tube BACTEC 960 with Lowenstein-Jensen method for diagnosis of Mycobacterium tuberculosis at Ethiopian National Tuberculosis Reference Laboratory, Addis Ababa, Ethiopia. BMC Res Notes 2017; 10(1): 181.","DOI":"10.1186\/s13104-017-2497-9"},{"key":"ref17","unstructured":"17. Chihota VN, Grant AD, Fielding K, et al. Liquid vs. solid culture for tuberculosis: performance and cost in a resource-constrained setting. Int J Tuberc Lung Dis 2010; 14(8): 1024-31. Figure Legends"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-6409041\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-6409041\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T02:33:36Z","timestamp":1744425216000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-6409041\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,12]]},"references-count":17,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-6409041\/v1","relation":{},"subject":[],"published":{"date-parts":[[2025,4,12]]},"subtype":"preprint"}}